SynthesisNeurology2021
Phenotypic and Genotypic Associations Between Migraine and Lipoprotein Subfractions.
Open access · greenAbstract readMeta-Analysis
In one paragraph
Synthesis in Neurology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers, 2 of them syntheses that pooled it.
0numbers the graph read from it
0cells of the map it votes in
16citing papers in PubMed, 2 pooled it
13.7field-weighted citation impact, top 1% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 2 syntheses or guidelines pooled it, 75 citations in OpenAlex.
- A multi-ancestry meta genome-wide association study of migraine among veterans: associations with traumatic brain injury, depression, and post-traumatic stress disorder.Molecular psychiatry · 2026Pooled it
- HMG-CoA reductase is a potential therapeutic target for migraine: a mendelian randomization study.Scientific reports · 2024Pooled it
- Plasma metabolomic signatures of migraine in 479,760 adults.iScience · 2026Article
- Metabolomic insights into migraine: mechanisms and biomarkers from in vivo and clinical studies.Metabolic brain disease · 2026Review
- Episodic migraine is associated with a more atherogenic lipid profile rather than independent insulin resistance: a case-control study.Lipids in health and disease · 2026Article
- Decoding the lipid-migraine link: a genetic and lipidomic investigation of migraine subtypes.Journal of oral & facial pain and headache · 2026Article
- The relationship between triglyceride levels and medication overuse headache in patients with chronic migraine.Journal of oral & facial pain and headache · 2026Article
- Conventional and genetic association between migraine and stroke with druggable genome-wide Mendelian randomization.Human genetics · 2025Article
- Mendelian randomization analysis reveals causal effects of migraine and its subtypes on early-onset ischemic stroke risk.Scientific reports · 2024Article
- Association between severe headache or migraine and lipid accumulation product and visceral adiposity index in adults: a cross-sectional study from NHANES.Lipids in health and disease · 2024Article
- Identifying therapeutic target genes for migraine by systematic druggable genome-wide Mendelian randomization.The journal of headache and pain · 2024Article
- Cis-eQTLs in seven duck tissues identify novel candidate genes for growth and carcass traits.BMC genomics · 2024Article
- Identification of genetic susceptibility for Chinese migraine with depression using machine learning.Frontiers in neurology · 2024Article
- Comprehensive analysis of genetic associations and single-cell expression profiles reveals potential links between migraine and multiple diseases: a phenome-wide association study.Frontiers in neurology · 2024Article
- Lipids, lipid-modifying drug target genes and migraine: a Mendelian randomization study.The journal of headache and pain · 2023Article
- Genetics of migraine: where are we now?The journal of headache and pain · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 1 institution in 1 country.
Yanjun GuoFrom the Division of Preventive Medicine (Y.G., I.D., F.G., P.M. Ridker, S.M., P.M. Rist, D.I.C.), Center for Cardiovascular Disease Prevention (P.M. Ridker, S.M., D.I.C.), and Center for Lipid Metabolomics (S.M.), Brigham and Women's Hospital; Harvard Medical School (Y.G., I.D., P.M. Ridker, S.M., P.M. Rist, D.I.C.); Department of Epidemiology (Y.G., T.K., P.R., D.I.C.), Harvard T.H. Chan School of Public Health; Genetics and Pharmacogenomics (P.G.), Merck & Co., Inc., Boston, MA; and Institute of Public Health (T.K.), Charité Universitätsmedizin Berlin, Germany.ORCID 0000-0002-5927-778X
Iyas DaghlasFrom the Division of Preventive Medicine (Y.G., I.D., F.G., P.M. Ridker, S.M., P.M. Rist, D.I.C.), Center for Cardiovascular Disease Prevention (P.M. Ridker, S.M., D.I.C.), and Center for Lipid Metabolomics (S.M.), Brigham and Women's Hospital; Harvard Medical School (Y.G., I.D., P.M. Ridker, S.M., P.M. Rist, D.I.C.); Department of Epidemiology (Y.G., T.K., P.R., D.I.C.), Harvard T.H. Chan School of Public Health; Genetics and Pharmacogenomics (P.G.), Merck & Co., Inc., Boston, MA; and Institute of Public Health (T.K.), Charité Universitätsmedizin Berlin, Germany.
Padhraig GormleyFrom the Division of Preventive Medicine (Y.G., I.D., F.G., P.M. Ridker, S.M., P.M. Rist, D.I.C.), Center for Cardiovascular Disease Prevention (P.M. Ridker, S.M., D.I.C.), and Center for Lipid Metabolomics (S.M.), Brigham and Women's Hospital; Harvard Medical School (Y.G., I.D., P.M. Ridker, S.M., P.M. Rist, D.I.C.); Department of Epidemiology (Y.G., T.K., P.R., D.I.C.), Harvard T.H. Chan School of Public Health; Genetics and Pharmacogenomics (P.G.), Merck & Co., Inc., Boston, MA; and Institute of Public Health (T.K.), Charité Universitätsmedizin Berlin, Germany.
Franco GiulianiniFrom the Division of Preventive Medicine (Y.G., I.D., F.G., P.M. Ridker, S.M., P.M. Rist, D.I.C.), Center for Cardiovascular Disease Prevention (P.M. Ridker, S.M., D.I.C.), and Center for Lipid Metabolomics (S.M.), Brigham and Women's Hospital; Harvard Medical School (Y.G., I.D., P.M. Ridker, S.M., P.M. Rist, D.I.C.); Department of Epidemiology (Y.G., T.K., P.R., D.I.C.), Harvard T.H. Chan School of Public Health; Genetics and Pharmacogenomics (P.G.), Merck & Co., Inc., Boston, MA; and Institute of Public Health (T.K.), Charité Universitätsmedizin Berlin, Germany.
Paul M RidkerFrom the Division of Preventive Medicine (Y.G., I.D., F.G., P.M. Ridker, S.M., P.M. Rist, D.I.C.), Center for Cardiovascular Disease Prevention (P.M. Ridker, S.M., D.I.C.), and Center for Lipid Metabolomics (S.M.), Brigham and Women's Hospital; Harvard Medical School (Y.G., I.D., P.M. Ridker, S.M., P.M. Rist, D.I.C.); Department of Epidemiology (Y.G., T.K., P.R., D.I.C.), Harvard T.H. Chan School of Public Health; Genetics and Pharmacogenomics (P.G.), Merck & Co., Inc., Boston, MA; and Institute of Public Health (T.K.), Charité Universitätsmedizin Berlin, Germany.
Samia MoraFrom the Division of Preventive Medicine (Y.G., I.D., F.G., P.M. Ridker, S.M., P.M. Rist, D.I.C.), Center for Cardiovascular Disease Prevention (P.M. Ridker, S.M., D.I.C.), and Center for Lipid Metabolomics (S.M.), Brigham and Women's Hospital; Harvard Medical School (Y.G., I.D., P.M. Ridker, S.M., P.M. Rist, D.I.C.); Department of Epidemiology (Y.G., T.K., P.R., D.I.C.), Harvard T.H. Chan School of Public Health; Genetics and Pharmacogenomics (P.G.), Merck & Co., Inc., Boston, MA; and Institute of Public Health (T.K.), Charité Universitätsmedizin Berlin, Germany.ORCID 0000-0001-6283-0980
Tobias KurthFrom the Division of Preventive Medicine (Y.G., I.D., F.G., P.M. Ridker, S.M., P.M. Rist, D.I.C.), Center for Cardiovascular Disease Prevention (P.M. Ridker, S.M., D.I.C.), and Center for Lipid Metabolomics (S.M.), Brigham and Women's Hospital; Harvard Medical School (Y.G., I.D., P.M. Ridker, S.M., P.M. Rist, D.I.C.); Department of Epidemiology (Y.G., T.K., P.R., D.I.C.), Harvard T.H. Chan School of Public Health; Genetics and Pharmacogenomics (P.G.), Merck & Co., Inc., Boston, MA; and Institute of Public Health (T.K.), Charité Universitätsmedizin Berlin, Germany.ORCID 0000-0001-7169-2620
Pamela M RistFrom the Division of Preventive Medicine (Y.G., I.D., F.G., P.M. Ridker, S.M., P.M. Rist, D.I.C.), Center for Cardiovascular Disease Prevention (P.M. Ridker, S.M., D.I.C.), and Center for Lipid Metabolomics (S.M.), Brigham and Women's Hospital; Harvard Medical School (Y.G., I.D., P.M. Ridker, S.M., P.M. Rist, D.I.C.); Department of Epidemiology (Y.G., T.K., P.R., D.I.C.), Harvard T.H. Chan School of Public Health; Genetics and Pharmacogenomics (P.G.), Merck & Co., Inc., Boston, MA; and Institute of Public Health (T.K.), Charité Universitätsmedizin Berlin, Germany.
Daniel I ChasmanFrom the Division of Preventive Medicine (Y.G., I.D., F.G., P.M. Ridker, S.M., P.M. Rist, D.I.C.), Center for Cardiovascular Disease Prevention (P.M. Ridker, S.M., D.I.C.), and Center for Lipid Metabolomics (S.M.), Brigham and Women's Hospital; Harvard Medical School (Y.G., I.D., P.M. Ridker, S.M., P.M. Rist, D.I.C.); Department of Epidemiology (Y.G., T.K., P.R., D.I.C.), Harvard T.H. Chan School of Public Health; Genetics and Pharmacogenomics (P.G.), Merck & Co., Inc., Boston, MA; and Institute of Public Health (T.K.), Charité Universitätsmedizin Berlin, Germany. dchasman@research.bwh.harvard.edu.ORCID 0000-0003-3357-0862
Merck & Co., Inc., Rahway, NJ, USA (United States) · US
Funding
The Women's Health Study: Infrastructure Support for Continued Cohort Follow-upUM1CA182913 · NCI · BRIGHAM AND WOMEN'S HOSPITAL · PI BURING, JULIE E., LEE, I-MIN · 2014 to 2018
$4.0MReducing Inflammation for the Prevention of CVD: A Focus on Eicosanoid PathwaysR01HL134811 · NHLBI · BRIGHAM AND WOMEN'S HOSPITAL · PI MORA, SAMIA · 2017 to 2020
$3.0MCirculating plasma metabolites, diet, and risk of type 2 diabetesR01DK112940 · NIDDK · BRIGHAM AND WOMEN'S HOSPITAL · PI HU, FRANK B, MORA, SAMIA · 2018 to 2021
$2.9MPatient Centered Approaches to Preventing ASCVD EventsK24HL136852 · NHLBI · BRIGHAM AND WOMEN'S HOSPITAL · PI SAMIA MORA · 2018 to 2026
$1.1MEffects of Vitamin D and Omega-3 on Cerebrovascular DiseaseK01HL128791 · NHLBI · BRIGHAM AND WOMEN'S HOSPITAL · PI RIST, PAMELA M. · 2016 to 2020
$858kCausality and/or shared physiology linking plasma lipids and blood pressure to migraineR21NS104398 · NINDS · BRIGHAM AND WOMEN'S HOSPITAL · PI CHASMAN, DANIEL IAN · 2018 to 2019
$492kMedical Research Council MC_PC_17228Medical Research Council MC_QA137853NCI NIH HHS UM1 CA182913NHLBI NIH HHS K01 HL128791NHLBI NIH HHS K24 HL136852NHLBI NIH HHS R01 HL134811NIDDK NIH HHS R01 DK112940NINDS NIH HHS R21 NS104398
Abstract
BACKGROUND AND
objectiveTo evaluate phenotypic and genetic relationships between migraine and lipoprotein subfractions.
methodsWe evaluated phenotypic associations between migraine and 19 lipoprotein subfraction measures in the Women's Genome Health Study (n = 22,788). We then investigated genetic relationships between these traits using summary statistics from the International Headache Genetics Consortium for migraine (n
resultsThere was a significant phenotypic association (odds ratio 1.27 [95% confidence interval 1.12-1.44]) and a significant genetic correlation at 0.18 (
conclusionsThe study supports the association between certain lipoprotein subfractions, especially for TRLP, and migraine in populations of European ancestry. The corresponding shared genetic components may help identify potential targets for future migraine therapeutics. CLASSIFICATION OF EVIDENCE: This study provides Class I evidence that migraine is significantly associated with some lipoprotein subfractions.
Indexed as
Genome-Wide Association StudyMigraine DisordersFemaleGenotypeHumansLipoproteinsPhenotypeLipoproteins
Identifiers
What Socratic holds
Textmetadata
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.